Quotes 5-day view Delayed Nyse
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
220.3(c)
216.88(c)
216.48(c)
213.28(c)
211.62(c)
Last
320 387
337 521
435 928
420 714
388 805
Volume
+0.62% -1.55% -0.18% -1.48% -0.78% Change
Sales 2021
3 144 M - -
Net income 2021
694 M - -
Net Debt 2021
249 M - -
P/E ratio 2021
44,9x
Yield 2021
0,76%
Sales 2022
3 412 M - -
Net income 2022
755 M - -
Net cash position 2022
219 M - -
P/E ratio 2022
42,5x
Yield 2022
0,86%
Capitalization
30 667 M 30 667 M -
EV / Sales 2021
9,83x
EV / Sales 2022
8,92x
Nbr of Employees
7 770
Free-Float
77,0%
ResMed specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (52.2%);
- masks (37.2%);
- software as a service (10.6%).
At the end of June 2019, the group had 6 production sites located in the United States, Australia, France, China,...
Notations Surperformance© of ResMed, Inc.
Trading Rating : Investor Rating :
All news about RESMED, INC.
News in other languages on RESMED, INC.
Analyst Recommendations on RESMED, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends RESMED, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
10
Average target price
182,86 $
Last Close Price
211,62 $
Spread / Highest target
3,96%
Spread / Average Target
-13,6%
Spread / Lowest Target
-34,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
